english.prescrire.org > Spotlight > Archives : 2023 > Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster

 COVID-19  The recombinant Beta variant covid-19 vaccine with AS03 adjuvant was authorised in the European Union in mid-November 2022, for use only as a booster in adults who have already received an mRNA or viral-vector vaccine.
Full article (2 pages) available for download by subscribers

The marketing authorisation for recombinant Beta variant covid-19 vaccine with AS03 adjuvant is not based on a comparative trial designed to evaluate its efficacy using clinical endpoints.

The immune response against Sars-CoV-2 after a booster dose of recombinant Beta variant covid-19 vaccine with AS03 adjuvant was mainly evaluated in 785 adults who took part in two immunogenicity studies and who had already received primary covid-19 vaccination, in most cases with an mRNA vaccine, 3 to 10 months previously.

©Prescrire 1 June 2023

Source: "Recombinant Beta variant covid-19 vaccine with adjuvant (Vidprevtyn Beta°), as a booster" Prescrire International 2023; 32 (249): 149-150. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter


For more information:

  COVID-19 
Follow Prescrire's
independent, evidence-based
analysis of the pandemic 
Free


Read more:

All the subjects in
Prescrire's Spotlight
Free >